+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 4Years +
All Genders
ID05163288

Phase III Study of N-Acetyl-L-Leucine Treatment for Niemann-Pick Disease Type C in Patients Aged 4 and Older

Led by IntraBio Inc · Updated on 2026-04-03

53

Participants Needed

14

Research Sites

24 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of N-acetyl-L-leucine IB1001 compared to standard care for patients aged 4 years and older diagnosed with Niemann-Pick disease type C NPC. This is a pivotal, randomized, double-blind, placebo-controlled, multi-center study designed to provide important information on this treatments impact on NPC symptoms. The study includes a crossover design where participants receive both the study drug and placebo during separate periods. Participants will take N-acetyl-L-leucine or a placebo orally as granules suspended in water, orange juice, or almond milk. Patients aged 13 and older will receive a total daily dose of 4 grams divided into three doses, while those under 13 will receive weight-based dosing. The study consists of a baseline period followed by two treatment periods of about 12 weeks each, where participants switch from one treatment to the other. After completing the parent study, some patients may join an open-label extension phase providing up to three years of treatment. During the trial, participants will undergo assessments at several points, including before and after each treatment period. These include scales measuring ataxia severity, functional ability, disability, clinical global impressions from physicians, caregivers, and patients, and quality of life questionnaires. Researchers will monitor adherence and safety throughout the study. The trial continues until December 2030, with careful evaluation of the primary outcomes after each treatment phase and ongoing follow-up for those in the extension phase.

CONDITIONS

Brief Title

A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

Research Team

M

Michael Strupp, MD

T

Taylor Fields

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here